GlassScriptPhysician profile
Brenda Rolander
NPI 1992718118
$2,398.67
in general payments reported to CMS, 2019-2025
29 companies · $443 in 2025
The $443 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $474 · 2022: $387 · 2023: $329 · 2024: $766 · 2025: $443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,537.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $488.61 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $317.02 | 2021-2025 | |
| Amgen INC. | $257.55 | 2021-2025 | Otezla, Repatha, Otezla |
| Exact Sciences Corporation | $224.88 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $156.95 | 2021-2022 | |
| Lilly USA, LLC | $155.42 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $91.41 | 2021-2024 | Airsupra, Breztri |
| Vanda Pharmaceuticals INC. | $68.43 | 2022 | |
| Merck Sharp & Dohme LLC | $67.49 | 2021-2024 | Gardasil, Gardasil 9, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.89 | 2021-2024 | Jardiance |
| Esperion Therapeutics, INC. | $52.68 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $51.88 | 2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $47.89 | 2022 | |
| Astellas Pharma US INC | $40.21 | 2023-2024 | Myrbetriq, Veozah |
| Ethicon US, LLC | $36.03 | 2023 | Linx Reflux Management System |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $33.38 | 2022-2025 | Freestyle Libre 3 |
| Neurocrine Biosciences, INC. | $32.76 | 2024 | Ingrezza |
| Medicomp INC | $26.13 | 2023 | Telepatch Cardiac Monitor |
| Aimmune Therapeutics, INC. | $21.14 | 2025 | Zenpep |
| Pfizer INC. | $19.64 | 2025 | |
| Xeris Pharmaceuticals, INC. | $18.93 | 2024 | Gvoke Hypopen |
| Lundbeck LLC | $16.91 | 2024 | Rexulti |
| Jazz Pharmaceuticals INC. | $16.31 | 2021 | |
| Sunovion Pharmaceuticals INC. | $15.75 | 2022 | |
| Almatica Pharma LLC | $15.68 | 2021 | |
| Sanofi-Aventis U.S. LLC | $15.49 | 2021 | |
| Amarin Pharma, INC. | $15.25 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.77 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $13.19 | 2023 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brenda Rolander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.